8 results about "Human fetal" patented technology

The invention relates to a construction method of a perfusion vascularized cervical cancer organoid chip, and relates to the technical field of biology. Comprising the following steps: S1, constructing a cervical cancer organ; s2, mixing the cervical cancer organ small cell cluster, the human umbilical vein endothelial cells and the human embryonic lung fibroblasts in proportion, and centrifugally gathering the mixed cells in a low-adsorption U-shaped plate to form a pre-vascularized cervical cancer organ; s3, re-suspending the pre-vascularized cervical cancer organoid and the human umbilical vein endothelial cells in the fibrous protein hydrogel, transferring the pre-vascularized cervical cancer organoid and the human umbilical vein endothelial cells into the organoid chip, and adding a vascularized cervical cancer organoid culture medium for culture, so that the endothelial cells form perfused blood vessels, and finally obtaining the perfused vascularized cervical cancer organoid chip. The prepared perfusion vascularized cervical cancer organoid can well solve the in-vitro vascularization problem of the organoid, simulates the in-vivo tumor angiogenesis process, is close to the in-vivo real tumor microenvironment, and provides technical support for exploration of cervical cancer disease mechanisms and related treatment.

The present application relates to a primer set for detecting multiple mutations of human embryo beta-thalassemia, a kit and application thereof. The primer set comprises five primers for amplifying HBB a plurality of mutations in the gene region: HBB-F1, HBB-F2, HBB-F3, HBB-R1 and HBB-R2, the sequences of which are shown in SEQ ID NO: 1-5 respectively; and eight primers for amplifying HBB linkage SNP sites within 1Mb range of the upstream and downstream genes: L1-F, L1-R, L2-F, L2-R, L3-F, L3-R, L4-F and L4-R, the sequences of which are shown in SEQ ID NO: 6-13 respectively. Based on the specific combination of long fragment PCR amplification and long fragment high-throughput sequencing, the present application can simultaneously detect multiple mutations of beta-thalassemia in multiple embryo samples with high specificity, accuracy and speed.

Methods and devices for reducing the risk of human fetal nerve injury during and prior to delivery are disclosed. The method comprises the steps of: (1) identifying the risk of nerve injury in a fetus during delivery by analyzing the blood of the fetus to determine at least a first excess alkali (BE) value of the fetus during a first period of time of a first delivery process; (2) determining a median multiple of the BE value for the first period of time by dividing the BE value by a median BE value of a dataset comprising a population of fetal BE values established during the first birth process for the same period of time as the first period of time, indicating that the fetus has a risk of nerve injury; (3) treating the fetus indicated by the identification step to be at risk of said nerve injury, where said treatment step comprises intervening in delivery by any conventional therapeutic measures to reduce or eliminate the risk of said nerve injury in said fetus.

The present application relates to a primer set for detecting multiple mutations of human embryo beta-thalassemia, a kit and application thereof. The primer set comprises five primers for amplifying HBB a plurality of mutations in the gene region: HBB-F1, HBB-F2, HBB-F3, HBB-R1 and HBB-R2, the sequences of which are shown in SEQ ID NO: 1-5 respectively; and eight primers for amplifying HBB linkage SNP sites within 1Mb range of the upstream and downstream genes: L1-F, L1-R, L2-F, L2-R, L3-F, L3-R, L4-F and L4-R, the sequences of which are shown in SEQ ID NO: 6-13 respectively. Based on the specific combination of long fragment PCR amplification and long fragment high-throughput sequencing, the present application can simultaneously detect multiple mutations of beta-thalassemia in multiple embryo samples with high specificity, accuracy and speed.

A neonate simulation device includes a physical fetal model and a virtual fetal model connected by a controller. The physical fetal model includes a skin, skeleton and internal electronic and mechanical components that are arranged to simulate a human fetus. The virtual fetal modal is a digital twin of the physical fetal model. It receives inputs from sensors in the physical fetal model and compares them to expected thresholds. It also provides input controls to the physical fetal model according to preset scenarios.

Methods and apparatus for reducing the risk of neurological injury to a human fetus during and before labor are disclosed. According to one embodiment, the method comprises the following steps: (1) identifying a risk of neurological injury to a fetus during labor by analyzing fetal blood during a first time period of a first stage of labor to determine at least a first base excess (BE) value for the fetus; (2) determining a median multiple of the BE value for the first time period by dividing the BE value by the median BE value of a data set, the data set comprising a population of fetal BE values established for a time period during the first stage of labor that is the same as the first time period, wherein a BE value that is a predefined median multiple of the BE value indicates that the fetus is at risk of neurological injury; and (3) treating the fetus indicated by the identifying step to be at risk of neurological injury, wherein the treating step comprises intervening in labor by any conventional treatment measure to reduce or eliminate the risk of neurological injury to the fetus.

A method to detect immune health status in a human infant or child, and compositions and methods to improve health status in a human fetus, infant or child, as well as compositions and methods useful to improve immune health status, are provided.